Neptune Wellness Solutions Inc (NQ: NEPT )
0.1880 +0.0105 (+5.92%) Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2023 Add to My Watchlist
All News about Neptune Wellness Solutions Inc
Neptune Wellness (NASDAQ: NEPT) Is Capitalizing On High-Demand, Non-Discretionary Organic Baby Food Industry
June 02, 2023
There are some industries that can withstand economic downturns, continue to succeed and sometimes even thrive. Simply put, these non-discretionary industries are essential, and consumer purchasing...
Neptune Wellness Solns's Earnings Outlook
December 15, 2022
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Why Minerva Surgical Shares Are Trading Higher By 166%; Here Are 26 Stocks Moving Premarket
December 28, 2022
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 166% to $0.4327 in pre-market trading after the company reported a $30 million private placement of common stock led by Accelmed Partners.
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
December 28, 2022
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal...
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
December 27, 2022
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following